These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23579216)

  • 1. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms.
    Khan MS; Luong TV; Watkins J; Toumpanakis C; Caplin ME; Meyer T
    Br J Cancer; 2013 May; 108(9):1838-45. PubMed ID: 23579216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
    Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
    World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors.
    Philips P; Kooby DA; Maithel S; Merchant NB; Weber SM; Winslow ER; Ahmad S; Kim HJ; Scoggins CR; McMasters KM; Martin RCG
    Pancreas; 2018 Mar; 47(3):326-331. PubMed ID: 29351120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grade Assignment by Ki-67 Proliferative Index, Mitotic Count, and Phosphohistone H3 Count in Surgically Resected Gastrointestinal and Pancreatic Neuroendocrine Tumors.
    Murphy CE; McCormick KA; Shankaran V; Reddi DM; Swanson PE; Upton MP; Papanicolau-Sengos A; Khor S; Westerhoff M
    Pancreas; 2017; 46(10):1359-1365. PubMed ID: 29040195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
    Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
    BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors.
    Sun Y; Lohse C; Smyrk T; Hobday T; Kroneman T; Zhang L
    Am J Surg Pathol; 2018 Feb; 42(2):247-255. PubMed ID: 29016403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors.
    Gao SW; Huang CS; Huang XT; Chen LH; Chen W; Cai JP; Yin XY
    Pancreas; 2019 Jul; 48(6):795-798. PubMed ID: 31210659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
    Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
    Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.
    Zhao CL; Dabiri B; Hanna I; Lee L; Xiaofei Z; Hossein-Zadeh Z; Cao W; Allendorf J; Rodriguez AP; Weng K; Turunbedu S; Boyd A; Gupta M
    Ann Diagn Pathol; 2023 Aug; 65():152149. PubMed ID: 37119647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors?
    Dumars C; Foubert F; Touchefeu Y; Regenet N; Senellart H; Matysiak-Budnik T; Heymann MF
    Endocrine; 2016 Aug; 53(2):395-401. PubMed ID: 27048356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.
    Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G
    PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital image analysis of Ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms.
    Saetiew K; Angkathunyakul N; Hunnangkul S; Pongpaibul A
    Ann Diagn Pathol; 2024 Aug; 71():152295. PubMed ID: 38547761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.